Biogen BIIB Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Estimated additional payments upon achievement of development and commercial milestones by Product | ||||||
| Felzartamab | $730M— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Biogen break its business down?
- Biogen (BIIB) reports revenue by product across 2 parts — Contract manufacturing, royalty and other revenue and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Biogen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Biogen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
